<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutrients</journal-id><journal-id journal-id-type="iso-abbrev">Nutrients</journal-id><journal-id journal-id-type="publisher-id">nutrients</journal-id><journal-title-group><journal-title>Nutrients</journal-title></journal-title-group><issn pub-type="epub">2072-6643</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29439526</article-id><article-id pub-id-type="pmc">5852777</article-id><article-id pub-id-type="doi">10.3390/nu10020201</article-id><article-id pub-id-type="publisher-id">nutrients-10-00201</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Effect of Oligofructose-Enriched Inulin on Faecal Bacterial Counts and Microbiota-Associated Characteristics in Celiac Disease Children Following a Gluten-Free Diet: Results of a Randomized, Placebo-Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5324-5982</contrib-id><name><surname>Drabińska</surname><given-names>Natalia</given-names></name><xref ref-type="aff" rid="af1-nutrients-10-00201">1</xref></contrib><contrib contrib-type="author"><name><surname>Jarocka-Cyrta</surname><given-names>Elżbieta</given-names></name><xref ref-type="aff" rid="af2-nutrients-10-00201">2</xref></contrib><contrib contrib-type="author"><name><surname>Markiewicz</surname><given-names>Lidia Hanna</given-names></name><xref ref-type="aff" rid="af3-nutrients-10-00201">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8580-2851</contrib-id><name><surname>Krupa-Kozak</surname><given-names>Urszula</given-names></name><xref ref-type="aff" rid="af1-nutrients-10-00201">1</xref><xref rid="c1-nutrients-10-00201" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-nutrients-10-00201"><label>1</label>Department of Chemistry and Biodynamics of Food, Institute of Animal Reproduction and Food Research of Polish Academy of Sciences, Tuwima 10 Str., 10-748 Olsztyn, Poland; <email>n.drabinska@pan.olsztyn.pl</email></aff><aff id="af2-nutrients-10-00201"><label>2</label>Department of Pediatrics, Gastroenterology and Nutrition, Collegium Medicum, University of Warmia &amp; Mazury, Oczapowskiego 2 Str., 10-719 Olsztyn, Poland; <email>ejarocka@op.pl</email></aff><aff id="af3-nutrients-10-00201"><label>3</label>Department of Immunology and Food Microbiology, Institute of Animal Reproduction and Food Research of Polish Academy of Sciences, Tuwima 10 Str., 10-748 Olsztyn, Poland; <email>l.markiewicz@pan.olsztyn.pl</email></aff><author-notes><corresp id="c1-nutrients-10-00201"><label>*</label>Correspondence: <email>u.krupa-kozak@pan.olsztyn.pl</email>; Tel.: +48-89-523-46-18</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2018</year></pub-date><volume>10</volume><issue>2</issue><elocation-id>201</elocation-id><history><date date-type="received"><day>15</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>10</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>© 2018 by the authors.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><offsets xml_i="4070" xml_f="4946" txt_i="11" txt_f="887">Celiac disease (CD) is associated with intestinal microbiota alterations. The administration of prebiotics could be a promising method of restoring gut homeostasis in CD. The aim of this study was to evaluate the effect of prolonged oligofructose-enriched inulin (Synergy 1) administration on the characteristics and metabolism of intestinal microbiota in CD children following a gluten-free diet (GFD). Thirty-four paediatric CD patients (mean age 10 years; 62% females) on a GFD were randomized into two experimental groups receiving Synergy 1 (10 g/day) or placebo (maltodextrin; 7 g/day) for 3 months. The quantitative gut microbiota characteristics and short-chain fatty acids (SCFAs) concentration were analysed. In addition, side effects were monitored. Generally, the administration of Synergy 1 in a GFD did not cause any side effects. After the intervention period, </offsets><italic><offsets xml_i="4954" xml_f="4969" txt_i="887" txt_f="902">Bifidobacterium</offsets></italic><offsets xml_i="4978" xml_f="5010" txt_i="902" txt_f="934"> count increased significantly (</offsets><italic><offsets xml_i="5018" xml_f="5019" txt_i="934" txt_f="935">p</offsets></italic><offsets xml_i="5028" xml_f="5457" txt_i="935" txt_f="1361"> &lt; 0.05) in the Synergy 1 group. Moreover, an increase in faecal acetate and butyrate levels was observed in the prebiotic group. Consequently, total SCFA levels were 31% higher than at the baseline. The presented trial shows that Synergy 1 applied as a supplement of a GFD had a moderate effect on the qualitative characteristics of faecal microbiota, whereas it stimulated the bacterial metabolite production in CD children.</offsets></p></abstract><kwd-group><kwd>celiac disease</kwd><kwd>inulin</kwd><kwd>prebiotic</kwd><kwd>gluten-free diet</kwd><kwd>gut microbiota</kwd><kwd>short-chain fatty acids</kwd></kwd-group></article-meta></front><body><sec id="sec1-nutrients-10-00201"><title><offsets xml_i="5713" xml_f="5728" txt_i="1369" txt_f="1384">1. Introduction</offsets></title><p><offsets xml_i="5739" xml_f="5839" txt_i="1385" txt_f="1485">Recent data emphasizes the pivotal role of microbiota homeostasis in maintaining the host’s health [</offsets><xref rid="B1-nutrients-10-00201" ref-type="bibr"><offsets xml_i="5889" xml_f="5890" txt_i="1485" txt_f="1486">1</offsets></xref><offsets xml_i="5897" xml_f="5898" txt_i="1486" txt_f="1487">,</offsets><xref rid="B2-nutrients-10-00201" ref-type="bibr"><offsets xml_i="5948" xml_f="5949" txt_i="1487" txt_f="1488">2</offsets></xref><offsets xml_i="5956" xml_f="6196" txt_i="1488" txt_f="1728">]. Commensal bacteria prevent the development of pathologic bacteria in the gut. Additionally, the intestinal microbiome is involved in the differentiation and proliferation of intestinal epithelial cells, the maintenance of gut integrity [</offsets><xref rid="B1-nutrients-10-00201" ref-type="bibr"><offsets xml_i="6246" xml_f="6247" txt_i="1728" txt_f="1729">1</offsets></xref><offsets xml_i="6254" xml_f="6709" txt_i="1729" txt_f="2184">], the synthesis of vital nutrients, in particular vitamins (B-complex vitamins, vitamin K), the absorption of minerals (calcium, magnesium), and the fermentation of food. Therefore, a dysbiotic intestinal microbiota may contribute to the development of gastrointestinal, systemic, and metabolic diseases. It has been reported that disruptions in microbiota composition during infancy may contribute to autoimmune diseases, including celiac disease (CD) [</offsets><xref rid="B3-nutrients-10-00201" ref-type="bibr"><offsets xml_i="6759" xml_f="6760" txt_i="2184" txt_f="2185">3</offsets></xref><offsets xml_i="6767" xml_f="6769" txt_i="2185" txt_f="2187">].</offsets></p><p><offsets xml_i="6776" xml_f="6894" txt_i="2188" txt_f="2306">CD is one of the most common chronic and diet-related disorders, affecting approximately 1% of the global population [</offsets><xref rid="B4-nutrients-10-00201" ref-type="bibr"><offsets xml_i="6944" xml_f="6945" txt_i="2306" txt_f="2307">4</offsets></xref><offsets xml_i="6952" xml_f="7280" txt_i="2307" txt_f="2635">]. In predisposed individuals, the ingestion of gluten-containing foods results in autoimmune enteropathy manifested by a variety of intestinal and extra-intestinal symptoms. The role of intestinal microbiota in CD aetiology is unclear, and it remains unknown whether microbiota dysbiosis is the cause or the consequence of CD [</offsets><xref rid="B5-nutrients-10-00201" ref-type="bibr"><offsets xml_i="7330" xml_f="7331" txt_i="2635" txt_f="2636">5</offsets></xref><offsets xml_i="7338" xml_f="7481" txt_i="2636" txt_f="2779">]. Literature data have demonstrated disproportions between Gram-negative and Gram-positive bacteria and a lower number of beneficial strains (</offsets><italic><offsets xml_i="7489" xml_f="7504" txt_i="2779" txt_f="2794">Bifidobacterium</offsets></italic><offsets xml_i="7513" xml_f="7515" txt_i="2794" txt_f="2796">, </offsets><italic><offsets xml_i="7523" xml_f="7536" txt_i="2796" txt_f="2809">Lactobacillus</offsets></italic><offsets xml_i="7545" xml_f="7563" txt_i="2809" txt_f="2827">) in CD patients [</offsets><xref rid="B6-nutrients-10-00201" ref-type="bibr"><offsets xml_i="7613" xml_f="7614" txt_i="2827" txt_f="2828">6</offsets></xref><offsets xml_i="7621" xml_f="7622" txt_i="2828" txt_f="2829">,</offsets><xref rid="B7-nutrients-10-00201" ref-type="bibr"><offsets xml_i="7672" xml_f="7673" txt_i="2829" txt_f="2830">7</offsets></xref><offsets xml_i="7680" xml_f="7808" txt_i="2830" txt_f="2958">]. It has also been suggested that a gluten-free diet (GFD) itself can cause changes in the composition of intestinal bacteria [</offsets><xref rid="B8-nutrients-10-00201" ref-type="bibr"><offsets xml_i="7858" xml_f="7859" txt_i="2958" txt_f="2959">8</offsets></xref><offsets xml_i="7866" xml_f="7867" txt_i="2959" txt_f="2960">,</offsets><xref rid="B9-nutrients-10-00201" ref-type="bibr"><offsets xml_i="7917" xml_f="7918" txt_i="2960" txt_f="2961">9</offsets></xref><offsets xml_i="7925" xml_f="8033" txt_i="2961" txt_f="3069">]. In CD patients, microbiota dysbiosis continues to be observed even after long-term treatment with a GFD [</offsets><xref rid="B6-nutrients-10-00201" ref-type="bibr"><offsets xml_i="8083" xml_f="8084" txt_i="3069" txt_f="3070">6</offsets></xref><offsets xml_i="8091" xml_f="8092" txt_i="3070" txt_f="3071">,</offsets><xref rid="B10-nutrients-10-00201" ref-type="bibr"><offsets xml_i="8143" xml_f="8145" txt_i="3071" txt_f="3073">10</offsets></xref><offsets xml_i="8152" xml_f="8154" txt_i="3073" txt_f="3075">].</offsets></p><p><offsets xml_i="8161" xml_f="8285" txt_i="3076" txt_f="3200">Microbiota evaluations can be performed in two ways: by analysing bacterial composition or by analysing bacterial activity [</offsets><xref rid="B11-nutrients-10-00201" ref-type="bibr"><offsets xml_i="8336" xml_f="8338" txt_i="3200" txt_f="3202">11</offsets></xref><offsets xml_i="8345" xml_f="8484" txt_i="3202" txt_f="3341">]. Microbiota-associated characteristics (MAC) are defined as the features of the human body that are influenced by intestinal microbiota [</offsets><xref rid="B11-nutrients-10-00201" ref-type="bibr"><offsets xml_i="8535" xml_f="8537" txt_i="3341" txt_f="3343">11</offsets></xref><offsets xml_i="8544" xml_f="8754" txt_i="3343" txt_f="3553">]. The most widely applied MAC in human studies is the analysis of the profile and concentration of faecal short-chain fatty acids (SCFAs) representing the unabsorbed fraction of SCFAs in the intestinal tract [</offsets><xref rid="B12-nutrients-10-00201" ref-type="bibr"><offsets xml_i="8805" xml_f="8807" txt_i="3553" txt_f="3555">12</offsets></xref><offsets xml_i="8814" xml_f="9163" txt_i="3555" txt_f="3904">]. SCFAs are produced during the fermentation of carbohydrates by intestinal microbiota, and the main products are acetate, propionate, and butyrate. However, if the supply of carbohydrates is limited, the fermentation of other sources of energy, such as proteins and fats, occurs and results in the formation of branched-chain fatty acids (BCFAs) [</offsets><xref rid="B13-nutrients-10-00201" ref-type="bibr"><offsets xml_i="9214" xml_f="9216" txt_i="3904" txt_f="3906">13</offsets></xref><offsets xml_i="9223" xml_f="9225" txt_i="3906" txt_f="3908">].</offsets></p><p><offsets xml_i="9232" xml_f="9355" txt_i="3909" txt_f="4032">At present, there are no pharmacological agents against CD; therefore, a GFD is still the only available treatment for CD [</offsets><xref rid="B14-nutrients-10-00201" ref-type="bibr"><offsets xml_i="9406" xml_f="9408" txt_i="4032" txt_f="4034">14</offsets></xref><offsets xml_i="9415" xml_f="9845" txt_i="4034" txt_f="4464">]. The importance of microbiota in CD pathogenesis has shifted the researchers’ focus to the modification of the composition and activity of intestinal microbiota. The administration of probiotics and prebiotics could be proposed as a relatively simple method of improving bacterial composition. The application of certain probiotic bacteria was shown to successfully restore the balance in microbiota composition of CD patients [</offsets><xref rid="B15-nutrients-10-00201" ref-type="bibr"><offsets xml_i="9896" xml_f="9898" txt_i="4464" txt_f="4466">15</offsets></xref><offsets xml_i="9905" xml_f="9963" txt_i="4466" txt_f="4524">]. Prebiotics also confer many beneficial health effects [</offsets><xref rid="B16-nutrients-10-00201" ref-type="bibr"><offsets xml_i="10014" xml_f="10016" txt_i="4524" txt_f="4526">16</offsets></xref><offsets xml_i="10023" xml_f="10267" txt_i="4526" txt_f="4770">], but unlike probiotics they are not living organisms but naturally occurring food components that are selectively utilized by the host microbiota. Among prebiotics, inulin-type fructans are the most widely studied, and are proven to increase </offsets><italic><offsets xml_i="10275" xml_f="10290" txt_i="4770" txt_f="4785">Bifidobacterium</offsets></italic><offsets xml_i="10299" xml_f="10304" txt_i="4785" txt_f="4790"> and </offsets><italic><offsets xml_i="10312" xml_f="10325" txt_i="4790" txt_f="4803">Lactobacillus</offsets></italic><offsets xml_i="10334" xml_f="10361" txt_i="4803" txt_f="4830"> counts in faecal samples [</offsets><xref rid="B17-nutrients-10-00201" ref-type="bibr"><offsets xml_i="10412" xml_f="10414" txt_i="4830" txt_f="4832">17</offsets></xref><offsets xml_i="10421" xml_f="10561" txt_i="4832" txt_f="4972">]. Prebiotics have been successfully applied to restore the microbiota balance in patients suffering from inflammatory intestinal diseases [</offsets><xref rid="B18-nutrients-10-00201" ref-type="bibr"><offsets xml_i="10612" xml_f="10614" txt_i="4972" txt_f="4974">18</offsets></xref><offsets xml_i="10621" xml_f="10622" txt_i="4974" txt_f="4975">,</offsets><xref rid="B19-nutrients-10-00201" ref-type="bibr"><offsets xml_i="10673" xml_f="10675" txt_i="4975" txt_f="4977">19</offsets></xref><offsets xml_i="10682" xml_f="10927" txt_i="4977" txt_f="5222">], but to date they have not been evaluated in CD patients. Therefore, the aim of this study was to evaluate the effect of oligofructose-enriched inulin on the characteristics and activity of intestinal microbiota in CD children following a GFD.</offsets></p></sec><sec id="sec2-nutrients-10-00201"><title><offsets xml_i="10978" xml_f="11002" txt_i="5224" txt_f="5248">2. Materials and Methods</offsets></title><sec id="sec2dot1-nutrients-10-00201"><title><offsets xml_i="11055" xml_f="11074" txt_i="5249" txt_f="5268">2.1. Study Protocol</offsets></title><p><offsets xml_i="11085" xml_f="11238" txt_i="5269" txt_f="5422">Thirty-four children (aged 4 to 18 years; 62% females) diagnosed with CD and following a GFD for at least 6 months were randomly allocated to a placebo (</offsets><italic><offsets xml_i="11246" xml_f="11247" txt_i="5422" txt_f="5423">n</offsets></italic><offsets xml_i="11256" xml_f="11279" txt_i="5423" txt_f="5446"> = 16) or a Synergy 1 (</offsets><italic><offsets xml_i="11287" xml_f="11288" txt_i="5446" txt_f="5447">n</offsets></italic><offsets xml_i="11297" xml_f="11386" txt_i="5447" txt_f="5536"> = 18) group, according to the study protocol described in detail by Krupa-Kozak et al. [</offsets><xref rid="B20-nutrients-10-00201" ref-type="bibr"><offsets xml_i="11437" xml_f="11439" txt_i="5536" txt_f="5538">20</offsets></xref><offsets xml_i="11446" xml_f="11544" txt_i="5538" txt_f="5636">]. The demographic and anthropometric characteristics of patients have been presented previously [</offsets><xref rid="B20-nutrients-10-00201" ref-type="bibr"><offsets xml_i="11595" xml_f="11597" txt_i="5636" txt_f="5638">20</offsets></xref><offsets xml_i="11604" xml_f="11858" txt_i="5638" txt_f="5892">]. During the 3-month intervention, children of the placebo group consumed maltodextrin (7 g orally/day; Maltodextrin DE 20, Hotrimex, Konin, Poland), whereas children of the Synergy 1 group consumed oligofructose-enriched inulin (10 g orally/day; Orafti</offsets><sup><offsets xml_i="11863" xml_f="11864" txt_i="5892" txt_f="5893">®</offsets></sup><offsets xml_i="11870" xml_f="12661" txt_i="5893" txt_f="6684"> Synergy 1, Beneo, Tienen, Belgium) as a supplement of a GFD. Maltodextrin was selected as a placebo, as it is digested in the small intestine, contrary to prebiotics that reach the colon in intact form. Participants were asked to record the daily compliance with treatment as well as any adverse reactions occurring during the whole trial in the observation chart provided to each participant at the first visit. In addition, they filled out the authors’ original questionnaire concerning the last week of the study, which was aimed at assessing in detail any side-effects after the intake of supplement, such as discomfort, abdominal pain, and stool frequency and consistency. The last week was selected because the effect of the prebiotic was the most dominant at this stage of the study.</offsets></p></sec><sec id="sec2dot2-nutrients-10-00201"><title><offsets xml_i="12716" xml_f="12727" txt_i="6686" txt_f="6697">2.2. Ethics</offsets></title><p><offsets xml_i="12738" xml_f="13234" txt_i="6698" txt_f="7194">The participants’ parents and caregivers signed written consent forms during the enrolment visit. The experimental design and all procedures have been approved by the Bioethics Committee of the Faculty of Medical Sciences of the University of Warmia and Mazury in Olsztyn (permission No. 23/2015 of 16 June 2015). Study visits were coordinated with regular visits held every 3 months in a gastroenterology clinic. The study was registered at ClinicalTrials database under the number NCT03064997 [</offsets><xref rid="B21-nutrients-10-00201" ref-type="bibr"><offsets xml_i="13285" xml_f="13287" txt_i="7194" txt_f="7196">21</offsets></xref><offsets xml_i="13294" xml_f="13296" txt_i="7196" txt_f="7198">].</offsets></p></sec><sec id="sec2dot3-nutrients-10-00201"><title><offsets xml_i="13351" xml_f="13374" txt_i="7200" txt_f="7223">2.3. Samples Collection</offsets></title><p><offsets xml_i="13385" xml_f="13456" txt_i="7224" txt_f="7295">The details of sample collection were presented in Krupa-Kozak et al. [</offsets><xref rid="B20-nutrients-10-00201" ref-type="bibr"><offsets xml_i="13507" xml_f="13509" txt_i="7295" txt_f="7297">20</offsets></xref><offsets xml_i="13516" xml_f="13989" txt_i="7297" txt_f="7770">]. Briefly, faecal samples were collected from patients (at the baseline and at the end of experiment), transported to a laboratory on ice, and aliquoted separately for bacterial DNA isolation and SCFA analysis. For the genomic assay, approximately 100 mg of faeces was separated and stored at −80 °C. For the SCFA analysis, two aliquots of approximately 100 mg were weighted, and 150 μL of 10% formic acid was added to each sample as preservative before storage at −80 °C.</offsets></p></sec><sec id="sec2dot4-nutrients-10-00201"><title><offsets xml_i="14044" xml_f="14083" txt_i="7772" txt_f="7811">2.4. Isolation of Bacterial Genomic DNA</offsets></title><p><offsets xml_i="14094" xml_f="14557" txt_i="7812" txt_f="8275">Immediately before DNA isolation, samples were defrosted at room temperature. For a quantitative analysis of microbial characteristics, genomic bacterial DNA was isolated from faecal samples using a commercial kit designated for human faecal specimens (GeneMATRIX Stool DNA Purification Kit, EURx, Gdańsk, Poland) according to the manufacturer’s protocol using the bead-beating method and a Gyrator UNIPREP 3D vortex (UniEquip, Planegg, Germany) as described in [</offsets><xref rid="B22-nutrients-10-00201" ref-type="bibr"><offsets xml_i="14608" xml_f="14610" txt_i="8275" txt_f="8277">22</offsets></xref><offsets xml_i="14617" xml_f="14619" txt_i="8277" txt_f="8279">].</offsets></p></sec><sec id="sec2dot5-nutrients-10-00201"><title><offsets xml_i="14674" xml_f="14705" txt_i="8281" txt_f="8312">2.5. Quantitative Real-Time PCR</offsets></title><p><offsets xml_i="14716" xml_f="14946" txt_i="8313" txt_f="8543">The quantitative characteristics of intestinal bacteria were determined by the real-time polymerase chain reaction (RT-PCR) technique with the use of group-specific primers according to the procedure described by Fotschki et al. [</offsets><xref rid="B22-nutrients-10-00201" ref-type="bibr"><offsets xml_i="14997" xml_f="14999" txt_i="8543" txt_f="8545">22</offsets></xref><offsets xml_i="15006" xml_f="15208" txt_i="8545" txt_f="8747">] The DNA of predominant bacterial strains was used as a positive control and for the preparation of standard curves. Pure cultures of bacterial strains were cultivated as described by Fotschki et al. [</offsets><xref rid="B22-nutrients-10-00201" ref-type="bibr"><offsets xml_i="15259" xml_f="15261" txt_i="8747" txt_f="8749">22</offsets></xref><offsets xml_i="15268" xml_f="15384" txt_i="8749" txt_f="8865">] and DNA was isolated with the same method as applied for faecal samples. Total bacterial counts and the counts of </offsets><italic><offsets xml_i="15392" xml_f="15407" txt_i="8865" txt_f="8880">Bifidobacterium</offsets></italic><offsets xml_i="15416" xml_f="15427" txt_i="8880" txt_f="8891"> (BIF) and </offsets><italic><offsets xml_i="15435" xml_f="15448" txt_i="8891" txt_f="8904">Lactobacillus</offsets></italic><offsets xml_i="15457" xml_f="15476" txt_i="8904" txt_f="8923"> (LAC) genera, the </offsets><italic><offsets xml_i="15484" xml_f="15520" txt_i="8923" txt_f="8959">Bacteroides-Prevotella-Porphyromonas</offsets></italic><offsets xml_i="15529" xml_f="15551" txt_i="8959" txt_f="8981"> (BPP) group, and the </offsets><italic><offsets xml_i="15559" xml_f="15580" txt_i="8981" txt_f="9002">Clostridium coccoides</offsets></italic><offsets xml_i="15589" xml_f="15602" txt_i="9002" txt_f="9015"> (Ccocc) and </offsets><italic><offsets xml_i="15610" xml_f="15628" txt_i="9015" txt_f="9033">Clostridium leptum</offsets></italic><offsets xml_i="15637" xml_f="15766" txt_i="9033" txt_f="9162"> (Clept) groups were determined. Decimal dilutions of the DNA standard were used to plot a standard curve with each primer pair (</offsets><xref ref-type="table" rid="nutrients-10-00201-t001"><offsets xml_i="15819" xml_f="15826" txt_i="9162" txt_f="9169">Table 1</offsets></xref><offsets xml_i="15833" xml_f="16451" txt_i="9169" txt_f="9787">). To be able to compare samples to the standards, the extracted DNA was not normalized to keep the same isolation efficiency and amplification conditions, allowing for the quantitative analysis. Amplifications were performed in the Quant Studio 6 Flex real-time PCR system (Thermo Fisher, Warsaw, Poland) in a total volume of 20 μL (10 μL of SYBR Green Jump-Start Taq ReadyMix (Sigma-Aldrich, Saint Louis, MO, USA), 1 μL of 10-fold diluted DNA, 200 μM of each primer, and PCR-grade water). The temperature program was as follows: 1 cycle at 95 °C for 2 min, 40 cycles at 95 °C for 15 s, primer annealing temperature (</offsets><xref ref-type="table" rid="nutrients-10-00201-t001"><offsets xml_i="16504" xml_f="16511" txt_i="9787" txt_f="9794">Table 1</offsets></xref><offsets xml_i="16518" xml_f="16885" txt_i="9794" txt_f="10161">) for 1 min, and 72 °C for 30 s with signal acquisition. After each run, a melting curve was prepared to confirm the specificity of amplicons. The values were normalized according to the dilution and weight of the sample. The analyses were performed in duplicate, and final data were expressed as log10 of bacterial cells per gram of the sample on a wet weight basis.</offsets></p></sec><sec id="sec2dot6-nutrients-10-00201"><title><offsets xml_i="16940" xml_f="16982" txt_i="10163" txt_f="10205">2.6. Microbiota-Associated Characteristics</offsets></title><p><offsets xml_i="16993" xml_f="17120" txt_i="10206" txt_f="10333">Individual SCFAs in fecal samples were analysed by gas chromatography according to a modified method of Garcia-Villaba et al. [</offsets><xref rid="B28-nutrients-10-00201" ref-type="bibr"><offsets xml_i="17171" xml_f="17173" txt_i="10333" txt_f="10335">28</offsets></xref><offsets xml_i="17180" xml_f="17434" txt_i="10335" txt_f="10589">]. Briefly, faecal samples of approximately 100 mg and 500 μL of a mixture of acetone and 0.03 M oxalic acid (3:2 ratio) were homogenized with a vortex for 1 min. Acetone was found to better extract SCFA than all of the solvents proposed by the authors [</offsets><xref rid="B28-nutrients-10-00201" ref-type="bibr"><offsets xml_i="17485" xml_f="17487" txt_i="10589" txt_f="10591">28</offsets></xref><offsets xml_i="17494" xml_f="17690" txt_i="10591" txt_f="10787">]. Dilution with water gave unsatisfactory peak shapes; therefore, it was replaced by aqueous 0.03 M oxalic acid, which hardly improved peak shapes and allowed us to obtain higher levels of SCFA [</offsets><xref rid="B29-nutrients-10-00201" ref-type="bibr"><offsets xml_i="17741" xml_f="17743" txt_i="10787" txt_f="10789">29</offsets></xref><offsets xml_i="17750" xml_f="17925" txt_i="10789" txt_f="10964">]. Then, samples were centrifuged for 20 min at 13,400 rpm, and the supernatants were collected into chromatography vials and introduced to the gas chromatography (GC) system.</offsets></p><p><offsets xml_i="17932" xml_f="18753" txt_i="10965" txt_f="11786">The SCFAs were analysed in the Agilent 7890A gas chromatograph (Agilent, Wilmington, DE, USA) with a flame-ionization detector (FID) and the 7683B auto-injector. The compounds were separated in the SGE BP21 capillary column (SGE Analytical Science by Trajan, Ringwood, VIC, Australia; 30 m × 0.53 mm, film thickness: 0.5). The carrier gas was helium (Air Products and Chemicals, Allentown, PA, USA; 5 mL/min). The samples (0.5 µL) were injected in a split mode (10:1). The oven temperature was initially set at 85 °C, raised to 180 °C (6 °C/min), and maintained for 5 min. The injector temperature was 250 °C and the temperature of the flame ionization detector was 290 °C. External standards of acetic, propionic, butyric, isobutyric, valeric, and isovaleric acid were applied. The analyses were performed in triplicate.</offsets></p></sec><sec id="sec2dot7-nutrients-10-00201"><title><offsets xml_i="18808" xml_f="18833" txt_i="11788" txt_f="11813">2.7. Statistical Analysis</offsets></title><p><offsets xml_i="18844" xml_f="19066" txt_i="11814" txt_f="12036">The results of the quantitative analyses of faecal microbiota and SCFAs are expressed as means ± standard error of the mean (SEM). The data collected from subjects with reported 80% intake were used in the final analysis (</offsets><italic><offsets xml_i="19074" xml_f="19075" txt_i="12036" txt_f="12037">n</offsets></italic><offsets xml_i="19084" xml_f="19170" txt_i="12037" txt_f="12123"> = 25). Normal distribution of data was evaluated by the Shapiro–Wilk test. Student’s </offsets><italic><offsets xml_i="19178" xml_f="19179" txt_i="12123" txt_f="12124">t</offsets></italic><offsets xml_i="19188" xml_f="19214" txt_i="12124" txt_f="12150">-test or the Mann–Whitney </offsets><italic><offsets xml_i="19222" xml_f="19223" txt_i="12150" txt_f="12151">U</offsets></italic><offsets xml_i="19232" xml_f="19396" txt_i="12151" txt_f="12315"> test was applied to compare differences between groups, as appropriate. Differences within groups before and after intervention were determined with the Student’s </offsets><italic><offsets xml_i="19404" xml_f="19405" txt_i="12315" txt_f="12316">t</offsets></italic><offsets xml_i="19414" xml_f="19628" txt_i="12316" txt_f="12530">-test or the Wilcoxon test, as appropriate. All statistical analyses were conducted using Statistica v. 12 software (StatSoft, Krakow, Polska). The significance of differences between the samples was determined at </offsets><italic><offsets xml_i="19636" xml_f="19637" txt_i="12530" txt_f="12531">p</offsets></italic><offsets xml_i="19646" xml_f="19657" txt_i="12531" txt_f="12539"> &lt; 0.05.</offsets></p></sec></sec><sec id="sec3-nutrients-10-00201"><title><offsets xml_i="19714" xml_f="19724" txt_i="12542" txt_f="12552">3. Results</offsets></title><sec id="sec3dot1-nutrients-10-00201"><title><offsets xml_i="19777" xml_f="19806" txt_i="12553" txt_f="12582">3.1. Response to Intervention</offsets></title><p><offsets xml_i="19817" xml_f="20338" txt_i="12583" txt_f="13104">In general, Synergy 1 was well-accepted by trial participants and did not cause discomfort. Based on three-months of observation, no specific side-effects were observed, except for single episodes of abdominal pain or diarrhoea that were noticed occasionally in both experimental groups. In one child suffering from bloating and constipation before the enrolment, the alleviation of symptoms during the intake of Synergy 1 was noticed. The results of detailed observations of the last intervention week are summarised in </offsets><xref ref-type="table" rid="nutrients-10-00201-t002"><offsets xml_i="20391" xml_f="20398" txt_i="13104" txt_f="13111">Table 2</offsets></xref><offsets xml_i="20405" xml_f="20931" txt_i="13111" txt_f="13637">. Mild abdominal pain lasting for two subsequent days was reported in three children, both in the Synergy 1 and placebo groups. The defecation frequency was similar in both experimental groups; however, the consistency of stool in children on a GFD supplemented with Synergy 1 was usually described as normal (95% of the time), while in the placebo group the consistency of stool was perceived as normal only 69% of the time. Two participants reported discomfort after taking the placebo that was described as moderate nausea.</offsets></p></sec><sec id="sec3dot2-nutrients-10-00201"><title><offsets xml_i="20986" xml_f="21031" txt_i="13639" txt_f="13684">3.2. Quantitative Profile of Fecal Microbiota</offsets></title><p><offsets xml_i="21042" xml_f="21121" txt_i="13685" txt_f="13764">The quantitative profiles of faecal microbiota of CD children are presented at </offsets><xref ref-type="fig" rid="nutrients-10-00201-f001"><offsets xml_i="21172" xml_f="21180" txt_i="13764" txt_f="13772">Figure 1</offsets></xref><offsets xml_i="21187" xml_f="21456" txt_i="13772" txt_f="14041">. The initial total bacteria number (TBN) as well as the initial counts of individual bacteria were similar in both experimental groups. A comparison of bacteria counts between the experimental groups after the three-month intervention revealed a significant increase (</offsets><italic><offsets xml_i="21464" xml_f="21465" txt_i="14041" txt_f="14042">p</offsets></italic><offsets xml_i="21474" xml_f="22081" txt_i="14042" txt_f="14646"> &lt; 0.05) in BIF count in the Synergy 1 group. Moreover, the count of Clept in the Synergy 1 group was stable and at the end of experiment it was similar to the initial count, whereas in the placebo group the final Clept count was reduced. After the intervention, a decrease in the count of LAC was noticed in both experimental groups, but it was significant only in the Synergy 1 group. The determined alterations in the quantity of individual bacteria resulting from the intervention were reflected by the TBN, which remained constant in the Synergy 1 group, but tended to decrease in the placebo group.</offsets></p></sec><sec id="sec3dot3-nutrients-10-00201"><title><offsets xml_i="22136" xml_f="22177" txt_i="14648" txt_f="14689">3.3. Microbiota-Associated Charcteristics</offsets></title><p><offsets xml_i="22188" xml_f="22357" txt_i="14690" txt_f="14859">Based on the results of the gas chromatography analysis, acetic, propionic, and butyric acid were determined in dominant concentration in faecal samples of CD children (</offsets><xref ref-type="table" rid="nutrients-10-00201-t003"><offsets xml_i="22410" xml_f="22417" txt_i="14859" txt_f="14866">Table 3</offsets></xref><offsets xml_i="22424" xml_f="22568" txt_i="14866" txt_f="15010">). Initially, the concentration of individual SCFAs was statistically similar in both experimental groups. After the experiment, a significant (</offsets><italic><offsets xml_i="22576" xml_f="22577" txt_i="15010" txt_f="15011">p</offsets></italic><offsets xml_i="22586" xml_f="22844" txt_i="15011" txt_f="15266"> &lt; 0.05) increase in faecal acetate and butyrate levels was observed in the group receiving Synergy 1; consequently, total SCFAs concentration was 31% higher than at the baseline. A comparison of both groups after the intervention revealed significantly (</offsets><italic><offsets xml_i="22852" xml_f="22853" txt_i="15266" txt_f="15267">p</offsets></italic><offsets xml_i="22862" xml_f="23046" txt_i="15267" txt_f="15448"> &lt; 0.05) higher levels of acetate and propionate in the Synergy 1 group. At the end of experiment, the faecal concentration of total SCFAs in the Synergy 1 group was significantly (</offsets><italic><offsets xml_i="23054" xml_f="23055" txt_i="15448" txt_f="15449">p</offsets></italic><offsets xml_i="23064" xml_f="23109" txt_i="15449" txt_f="15491"> &lt; 0.05) higher than in the placebo group.</offsets></p><p><offsets xml_i="23116" xml_f="23181" txt_i="15492" txt_f="15557">The initial concentrations of total BCFAs, expressed as a sum of </offsets><italic><offsets xml_i="23189" xml_f="23192" txt_i="15557" txt_f="15560">iso</offsets></italic><offsets xml_i="23201" xml_f="23214" txt_i="15560" txt_f="15573">-butyric and </offsets><italic><offsets xml_i="23222" xml_f="23225" txt_i="15573" txt_f="15576">iso</offsets></italic><offsets xml_i="23234" xml_f="23292" txt_i="15576" txt_f="15634">-valeric acids, were similar in both experimental groups (</offsets><xref ref-type="table" rid="nutrients-10-00201-t003"><offsets xml_i="23345" xml_f="23352" txt_i="15634" txt_f="15641">Table 3</offsets></xref><offsets xml_i="23359" xml_f="23572" txt_i="15641" txt_f="15854">). After the intervention, the relative concentration of BCFAs, expressed as the percentage of the total BCFAs in the total SCFAs, decreased by 31% in the Synergy 1 group but increased by 15% in the placebo group.</offsets></p></sec></sec><sec id="sec4-nutrients-10-00201"><title><offsets xml_i="23629" xml_f="23642" txt_i="15857" txt_f="15870">4. Discussion</offsets></title><p><offsets xml_i="23653" xml_f="23743" txt_i="15871" txt_f="15961">Inulin-type fructans are one of the most widely researched groups of prebiotic compounds [</offsets><xref rid="B30-nutrients-10-00201" ref-type="bibr"><offsets xml_i="23794" xml_f="23796" txt_i="15961" txt_f="15963">30</offsets></xref><offsets xml_i="23803" xml_f="23917" txt_i="15963" txt_f="16077">]. Their positive effect in counteracting intestinal microbiota dysbiosis has been demonstrated in human studies [</offsets><xref rid="B31-nutrients-10-00201" ref-type="bibr"><offsets xml_i="23968" xml_f="23970" txt_i="16077" txt_f="16079">31</offsets></xref><offsets xml_i="23977" xml_f="24225" txt_i="16079" txt_f="16327">]. To the best of our knowledge, prebiotics have never been applied as a GFD supplement in CD patients. This study makes the first attempt to evaluate the effect of inulin-type fructans on gut microbiota characteristics and activity in CD children.</offsets></p><p><offsets xml_i="24232" xml_f="24586" txt_i="16328" txt_f="16682">The first finding to emerge from the present study was an increase in the count of BIF in children following a GFD supplemented with Synergy 1. Our results are consistent with published studies where inulin-type fructans had a stimulating effect on BIF species regardless of the applied dose, degree of polymerization, or the duration of the experiment [</offsets><xref rid="B32-nutrients-10-00201" ref-type="bibr"><offsets xml_i="24637" xml_f="24639" txt_i="16682" txt_f="16684">32</offsets></xref><offsets xml_i="24646" xml_f="24647" txt_i="16684" txt_f="16685">,</offsets><xref rid="B33-nutrients-10-00201" ref-type="bibr"><offsets xml_i="24698" xml_f="24700" txt_i="16685" txt_f="16687">33</offsets></xref><offsets xml_i="24707" xml_f="24826" txt_i="16687" txt_f="16806">]. In CD patients, both adults and children, a decrease in the counts and diversity of BIF species have been reported [</offsets><xref rid="B8-nutrients-10-00201" ref-type="bibr"><offsets xml_i="24876" xml_f="24877" txt_i="16806" txt_f="16807">8</offsets></xref><offsets xml_i="24884" xml_f="25242" txt_i="16807" txt_f="17165">]. Taking this into account, the obtained results are promising as they indicated that the administration of Synergy 1 in a GFD may counteract the reduction in BIF count in CD children. Much research has pointed out health-associated benefits of BIF and demonstrated the stimulation of immune response and suppression of pro-inflammatory cytokine synthesis [</offsets><xref rid="B34-nutrients-10-00201" ref-type="bibr"><offsets xml_i="25293" xml_f="25295" txt_i="17165" txt_f="17167">34</offsets></xref><offsets xml_i="25302" xml_f="25303" txt_i="17167" txt_f="17168">,</offsets><xref rid="B35-nutrients-10-00201" ref-type="bibr"><offsets xml_i="25354" xml_f="25356" txt_i="17168" txt_f="17170">35</offsets></xref><offsets xml_i="25363" xml_f="25364" txt_i="17170" txt_f="17171">,</offsets><xref rid="B36-nutrients-10-00201" ref-type="bibr"><offsets xml_i="25415" xml_f="25417" txt_i="17171" txt_f="17173">36</offsets></xref><offsets xml_i="25424" xml_f="25613" txt_i="17173" txt_f="17362">]. However, it is important to highlight that changes in microbiota resulting from a dietary intervention with a prebiotic depend among other factors on the initial microbiota composition [</offsets><xref rid="B37-nutrients-10-00201" ref-type="bibr"><offsets xml_i="25664" xml_f="25666" txt_i="17362" txt_f="17364">37</offsets></xref><offsets xml_i="25673" xml_f="25690" txt_i="17364" txt_f="17381">]. Tuohy et al. [</offsets><xref rid="B38-nutrients-10-00201" ref-type="bibr"><offsets xml_i="25741" xml_f="25743" txt_i="17381" txt_f="17383">38</offsets></xref><offsets xml_i="25750" xml_f="26260" txt_i="17383" txt_f="17893">] observed a significant increase in BIF count in healthy volunteers receiving 8 g of inulin for two weeks, but a more prominent increase was observed in subjects with lower initial bacterial counts. After analysing the count of other bacteria groups, a constant quantity in Clept was observed in the experimental group supplemented with Synergy 1, whereas a decreasing trend was observed in the placebo group. Clept is one of the predominant groups of gut bacteria, with a 16–25% share of the total bacteria [</offsets><xref rid="B39-nutrients-10-00201" ref-type="bibr"><offsets xml_i="26311" xml_f="26313" txt_i="17893" txt_f="17895">39</offsets></xref><offsets xml_i="26320" xml_f="26336" txt_i="17895" txt_f="17911">], and includes </offsets><italic><offsets xml_i="26344" xml_f="26372" txt_i="17911" txt_f="17939">Faecalibacterium prausnitzii</offsets></italic><offsets xml_i="26381" xml_f="26406" txt_i="17939" txt_f="17964"> and selected species of </offsets><italic><offsets xml_i="26414" xml_f="26425" txt_i="17964" txt_f="17975">Eubacterium</offsets></italic><offsets xml_i="26434" xml_f="26439" txt_i="17975" txt_f="17980"> and </offsets><italic><offsets xml_i="26447" xml_f="26459" txt_i="17980" txt_f="17992">Ruminococcus</offsets></italic><offsets xml_i="26468" xml_f="26470" txt_i="17992" txt_f="17994"> [</offsets><xref rid="B40-nutrients-10-00201" ref-type="bibr"><offsets xml_i="26521" xml_f="26523" txt_i="17994" txt_f="17996">40</offsets></xref><offsets xml_i="26530" xml_f="26686" txt_i="17996" txt_f="18152">]. Clept plays a vital role in the intestine. It is involved in the fermentation of unabsorbed carbohydrates, which leads to the formation of butyric acid [</offsets><xref rid="B41-nutrients-10-00201" ref-type="bibr"><offsets xml_i="26737" xml_f="26739" txt_i="18152" txt_f="18154">41</offsets></xref><offsets xml_i="26746" xml_f="26875" txt_i="18154" txt_f="18283">]. Changes in the composition and reduced counts of Clept group bacteria are characteristic of inflammatory intestinal diseases [</offsets><xref rid="B42-nutrients-10-00201" ref-type="bibr"><offsets xml_i="26926" xml_f="26928" txt_i="18283" txt_f="18285">42</offsets></xref><offsets xml_i="26935" xml_f="27170" txt_i="18285" txt_f="18520">]. Dietary intervention with the prebiotic Synergy 1 resulted in a decrease in the final LAC count, which was an unforeseen result as based on literature data, inulin-type fructans were expected to stimulate the growth of LAC species [</offsets><xref rid="B32-nutrients-10-00201" ref-type="bibr"><offsets xml_i="27221" xml_f="27223" txt_i="18520" txt_f="18522">32</offsets></xref><offsets xml_i="27230" xml_f="27262" txt_i="18522" txt_f="18554">]. In contrast, Adebola et al. [</offsets><xref rid="B43-nutrients-10-00201" ref-type="bibr"><offsets xml_i="27313" xml_f="27315" txt_i="18554" txt_f="18556">43</offsets></xref><offsets xml_i="27322" xml_f="27700" txt_i="18556" txt_f="18934">] demonstrated that inulin did not stimulate any of the five probiotic strains of LAC, while other potential prebiotics, including lactulose and lactobionic acid, were utilized by bacteria and minimized the adverse effects of bile acid stress. The cited authors concluded that LAC have potentially stimulating effects only in specific formulations of probiotics and prebiotics [</offsets><xref rid="B43-nutrients-10-00201" ref-type="bibr"><offsets xml_i="27751" xml_f="27753" txt_i="18934" txt_f="18936">43</offsets></xref><offsets xml_i="27760" xml_f="27806" txt_i="18936" txt_f="18982">]. A previous animal study on rats fed a GFD [</offsets><xref rid="B44-nutrients-10-00201" ref-type="bibr"><offsets xml_i="27857" xml_f="27859" txt_i="18982" txt_f="18984">44</offsets></xref><offsets xml_i="27866" xml_f="27933" txt_i="18984" txt_f="19051">] showed that diets containing inulin reduced the faecal LAC count.</offsets></p><p><offsets xml_i="27940" xml_f="28765" txt_i="19052" txt_f="19877">Although oligofructose-enriched inulin applied as a supplement of a GFD had a rather moderate effect on changes in the qualitative characteristics of faecal microbiota of CD children, it impacted considerably the bacteria activity and altered the amount of bacterial metabolites. We noticed a remarkable increase in the total SCFAs concentration in the Synergy 1 group, mainly due to a significant increase in acetate concentration. This result could be attributed to an effective fermentation of inulin-type fructans administered in a GFD, which are a readily available source of energy for gut microbiota. Our findings are in agreement with previous studies reporting that diet and dietary compounds can modulate the metabolic activity of the intestinal microbiota rather than its quantitative and qualitative composition [</offsets><xref rid="B45-nutrients-10-00201" ref-type="bibr"><offsets xml_i="28816" xml_f="28818" txt_i="19877" txt_f="19879">45</offsets></xref><offsets xml_i="28825" xml_f="28826" txt_i="19879" txt_f="19880">,</offsets><xref rid="B46-nutrients-10-00201" ref-type="bibr"><offsets xml_i="28877" xml_f="28879" txt_i="19880" txt_f="19882">46</offsets></xref><offsets xml_i="28886" xml_f="29369" txt_i="19882" txt_f="20365">]. On the other hand, it could be expected that the acidification of the intestinal environment as a result of excessive SCFAs production could be associated with changes in bacteria composition, and potentially may promote the growth of beneficial microbiota simultaneously reducing the number of pathogenic species. In the present study, the increase in SCFAs amount was accompanied with the rise of BIF quantity. Protective BIF are considered to be the main producers of acetate [</offsets><xref rid="B47-nutrients-10-00201" ref-type="bibr"><offsets xml_i="29420" xml_f="29422" txt_i="20365" txt_f="20367">47</offsets></xref><offsets xml_i="29429" xml_f="29505" txt_i="20367" txt_f="20443">]. Previously, acetic acid has been regarded as a pro-inflammatory trigger [</offsets><xref rid="B48-nutrients-10-00201" ref-type="bibr"><offsets xml_i="29556" xml_f="29558" txt_i="20443" txt_f="20445">48</offsets></xref><offsets xml_i="29565" xml_f="29658" txt_i="20445" txt_f="20538">] but recent studies have demonstrated that acetate can prevent enteropathogenic infections [</offsets><xref rid="B47-nutrients-10-00201" ref-type="bibr"><offsets xml_i="29709" xml_f="29711" txt_i="20538" txt_f="20540">47</offsets></xref><offsets xml_i="29718" xml_f="29878" txt_i="20540" txt_f="20700">]. The concentration of acetic acid is correlated with the expression of the Apoe, C3, and Pla2g2a genes, which are involved in the anti-inflammatory response [</offsets><xref rid="B47-nutrients-10-00201" ref-type="bibr"><offsets xml_i="29929" xml_f="29931" txt_i="20700" txt_f="20702">47</offsets></xref><offsets xml_i="29938" xml_f="29968" txt_i="20702" txt_f="20732">]. Moreover, acetate prevents </offsets><italic><offsets xml_i="29976" xml_f="29992" txt_i="20732" txt_f="20748">Escherichia coli</offsets></italic><offsets xml_i="30001" xml_f="30167" txt_i="20748" txt_f="20914"> O157-induced apoptosis of epithelial cells by decreasing transepithelial electrical resistance, and it is also involved in the reduction of intestinal permeability [</offsets><xref rid="B47-nutrients-10-00201" ref-type="bibr"><offsets xml_i="30218" xml_f="30220" txt_i="20914" txt_f="20916">47</offsets></xref><offsets xml_i="30227" xml_f="30376" txt_i="20916" txt_f="21065">]. Acetate has been detected in the circulation at a concentration of 50–150 μM, which could point to a systemic mechanism of microbiota regulation [</offsets><xref rid="B49-nutrients-10-00201" ref-type="bibr"><offsets xml_i="30427" xml_f="30429" txt_i="21065" txt_f="21067">49</offsets></xref><offsets xml_i="30436" xml_f="30662" txt_i="21067" txt_f="21293">]. The increase in acetic acid had the most dominant effect on the increase of total SCFAs. Consequently, the relative content of BCFAs was reduced after intervention, even though the concentration of BCFAs remained unchanged.</offsets></p><p><offsets xml_i="30669" xml_f="31047" txt_i="21294" txt_f="21672">The concentrations of propionate and butyrate also increased in subjects supplemented with Synergy 1. The above could be attributed to the formula of Synergy 1, which is a mixture of short-chain fructooligosaccharides and long-chain inulin. Butyric acid is the main fermentation product of oligosaccharides, whereas inulin fermentation leads to the formation of propionic acid [</offsets><xref rid="B50-nutrients-10-00201" ref-type="bibr"><offsets xml_i="31098" xml_f="31100" txt_i="21672" txt_f="21674">50</offsets></xref><offsets xml_i="31107" xml_f="31462" txt_i="21674" txt_f="22029">]. The importance of the increase in butyrate levels is associated with its role in the proliferation and differentiation of colon epithelial cells. Butyric acid regulates tight junction proteins and improves the integrity of the gut barrier by stimulating the expression of claudin-1 and zonula occludens-2, which participate in tight-junction assembly [</offsets><xref rid="B13-nutrients-10-00201" ref-type="bibr"><offsets xml_i="31513" xml_f="31515" txt_i="22029" txt_f="22031">13</offsets></xref><offsets xml_i="31522" xml_f="31610" txt_i="22031" txt_f="22119">]. Butyric acid has also been shown to alleviate gastrointestinal mucosal inflammation [</offsets><xref rid="B51-nutrients-10-00201" ref-type="bibr"><offsets xml_i="31661" xml_f="31663" txt_i="22119" txt_f="22121">51</offsets></xref><offsets xml_i="31670" xml_f="31672" txt_i="22121" txt_f="22123">].</offsets></p></sec><sec id="sec5-nutrients-10-00201"><title><offsets xml_i="31723" xml_f="31737" txt_i="22125" txt_f="22139">5. Conclusions</offsets></title><p><offsets xml_i="31748" xml_f="32267" txt_i="22140" txt_f="22659">In conclusion, the results of this study have demonstrated that the administration of oligofructose-enriched inulin is harmless and modulated the proportion of bacterial species in faecal samples, increasing the counts of BIF in paediatric CD patients adhering to a GFD. However, the main findings were related to the shifting the faecal concentrations of bacterial metabolites provoked by prebiotic administration. In this study, the addition of Synergy 1 to a GFD of CD children modified the faecal SCFA profile, in p</offsets><xref rid="B52-nutrients-10-00201" ref-type="bibr"><offsets xml_i="32318" xml_f="32320" txt_i="22659" txt_f="22661">52</offsets></xref><offsets xml_i="32327" xml_f="32844" txt_i="22661" txt_f="23178">], the application of prebiotics in a GFD may be helpful in the prevention of and protection against such possible complications. Admitting that the study reported herein has some limitations, in particular a small population size, inclusion of children with a wide age-range, and a relatively short intervention duration, the findings are interesting enough to encourage further well-powered intervention studies, which would provide sound data on the efficacy of prebiotic administration in the diet of CD patients.</offsets></p></sec></body><back><ack><title>Acknowledgments</title><p>We wish to thank sincerely all patients who participated in this study. The research was supported by statutory funds of the Department of Chemistry and Biodynamics of Food of the Institute of Animal Reproduction and Food Research, Polish Academy of Science (GW20).</p></ack><notes><title>Author Contributions</title><p>U.K.-K. conceived the study. U.K.-K., N.D. and E.J.-C. were involved in designing the study; N.D. and E.J.-C. carried out the study and collected samples; N.D. performed the main part of the experiments; L.H.M. performed the real-time PCR; U.K.-K. and N.D. analysed the data; N.D. drafted the manuscript, and U.K.-K., E.J.-C. and L.H.M. contributed to the further writing of the manuscript. All authors read and approved the final version of manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-nutrients-10-00201"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Hara</surname><given-names>A.M.</given-names></name><name><surname>Shanahan</surname><given-names>F.</given-names></name></person-group><article-title>Gut Microbiota: Mining for Therapeutic Potential</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2007</year><volume>5</volume><fpage>274</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2006.12.009</pub-id><pub-id pub-id-type="pmid">17368226</pub-id></element-citation></ref><ref id="B2-nutrients-10-00201"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jandhyala</surname><given-names>S.M.</given-names></name><name><surname>Talukdar</surname><given-names>R.</given-names></name><name><surname>Subramanyam</surname><given-names>C.</given-names></name><name><surname>Vuyyuru</surname><given-names>H.</given-names></name><name><surname>Sasikala</surname><given-names>M.</given-names></name><name><surname>Reddy</surname><given-names>D.N.</given-names></name></person-group><article-title>Role of the normal gut microbiota</article-title><source>World J. Gastroenterol.</source><year>2015</year><volume>21</volume><fpage>8836</fpage><lpage>8847</lpage><pub-id pub-id-type="doi">10.3748/wjg.v21.i29.8787</pub-id><pub-id pub-id-type="pmid">26269673</pub-id></element-citation></ref><ref id="B3-nutrients-10-00201"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonard</surname><given-names>M.M.</given-names></name><name><surname>Fasano</surname><given-names>A.</given-names></name></person-group><article-title>The microbiome as a possible target to prevent celiac disease</article-title><source>Expert Rev. Gastroenterol. Hepatol.</source><year>2016</year><volume>10</volume><fpage>555</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1586/17474124.2016.1166954</pub-id><pub-id pub-id-type="pmid">26999627</pub-id></element-citation></ref><ref id="B4-nutrients-10-00201"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gujral</surname><given-names>N.</given-names></name><name><surname>Freeman</surname><given-names>H.J.</given-names></name><name><surname>Thomson</surname><given-names>A.B.R.</given-names></name></person-group><article-title>Celiac disease: Prevalence, diagnosis, pathogenesis and treatment</article-title><source>World J. Gastroenterol.</source><year>2012</year><volume>18</volume><fpage>6036</fpage><lpage>6059</lpage><pub-id pub-id-type="doi">10.3748/wjg.v18.i42.6036</pub-id><pub-id pub-id-type="pmid">23155333</pub-id></element-citation></ref><ref id="B5-nutrients-10-00201"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marasco</surname><given-names>G.</given-names></name><name><surname>di Biase</surname><given-names>A.R.</given-names></name><name><surname>Schiumerini</surname><given-names>R.</given-names></name><name><surname>Eusebi</surname><given-names>L.H.</given-names></name><name><surname>Iughetti</surname><given-names>L.</given-names></name><name><surname>Ravaioli</surname><given-names>F.</given-names></name><name><surname>Scaioli</surname><given-names>E.</given-names></name><name><surname>Colecchia</surname><given-names>A.</given-names></name><name><surname>Festi</surname><given-names>D.</given-names></name></person-group><article-title>Gut microbiota and celiac disease</article-title><source>Dig. Dis. Sci.</source><year>2016</year><volume>61</volume><fpage>1461</fpage><lpage>1472</lpage><pub-id pub-id-type="doi">10.1007/s10620-015-4020-2</pub-id><pub-id pub-id-type="pmid">26725064</pub-id></element-citation></ref><ref id="B6-nutrients-10-00201"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Cagno</surname><given-names>R.</given-names></name><name><surname>de Angelis</surname><given-names>M.</given-names></name><name><surname>de Pasquale</surname><given-names>I.</given-names></name><name><surname>Ndagijimana</surname><given-names>M.</given-names></name><name><surname>Vernocchi</surname><given-names>P.</given-names></name><name><surname>Ricciuti</surname><given-names>P.</given-names></name><name><surname>Gagliardi</surname><given-names>F.</given-names></name><name><surname>Laghi</surname><given-names>L.</given-names></name><name><surname>Crecchio</surname><given-names>C.</given-names></name><name><surname>Guerzoni</surname><given-names>M.</given-names></name><etal></etal></person-group><article-title>Duodenal and faecal microbiota of celiac children: Molecular, phenotype and metabolome characterization</article-title><source>BMC Microbiol.</source><year>2011</year><volume>11</volume><elocation-id>219</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2180-11-219</pub-id><pub-id pub-id-type="pmid">21970810</pub-id></element-citation></ref><ref id="B7-nutrients-10-00201"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nistal</surname><given-names>E.</given-names></name><name><surname>Caminero</surname><given-names>A.</given-names></name><name><surname>Vivas</surname><given-names>S.</given-names></name><name><surname>Ruiz de Morales</surname><given-names>J.M.</given-names></name><name><surname>Sáenz de Miera</surname><given-names>L.E.</given-names></name><name><surname>Rodríguez-Aparicio</surname><given-names>L.B.</given-names></name><name><surname>Casqueiro</surname><given-names>J.</given-names></name></person-group><article-title>Differences in faecal bacteria populations and faecal bacteria metabolism in healthy adults and celiac disease patients</article-title><source>Biochimie</source><year>2012</year><volume>94</volume><fpage>1724</fpage><lpage>1729</lpage><pub-id pub-id-type="doi">10.1016/j.biochi.2012.03.025</pub-id><pub-id pub-id-type="pmid">22542995</pub-id></element-citation></ref><ref id="B8-nutrients-10-00201"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanz</surname><given-names>Y.</given-names></name><name><surname>Sánchez</surname><given-names>E.</given-names></name><name><surname>Marzotto</surname><given-names>M.</given-names></name><name><surname>Calabuig</surname><given-names>M.</given-names></name><name><surname>Torriani</surname><given-names>S.</given-names></name><name><surname>Dellaglio</surname><given-names>F.</given-names></name></person-group><article-title>Differences in faecal bacterial communities in coeliac and healthy children as detected by PCR and denaturing gradient gel electrophoresis</article-title><source>FEMS Immunol. Med. Microbiol.</source><year>2007</year><volume>51</volume><fpage>562</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1111/j.1574-695X.2007.00337.x</pub-id><pub-id pub-id-type="pmid">17919298</pub-id></element-citation></ref><ref id="B9-nutrients-10-00201"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Palma</surname><given-names>G.</given-names></name><name><surname>Nadal</surname><given-names>I.</given-names></name><name><surname>Medina</surname><given-names>M.</given-names></name><name><surname>Donat</surname><given-names>E.</given-names></name><name><surname>Ribes-Koninckx</surname><given-names>C.</given-names></name><name><surname>Calabuig</surname><given-names>M.</given-names></name><name><surname>Sanz</surname><given-names>Y.</given-names></name></person-group><article-title>Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children</article-title><source>BMC Microbiol.</source><year>2010</year><volume>10</volume><elocation-id>63</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2180-10-63</pub-id><pub-id pub-id-type="pmid">20181275</pub-id></element-citation></ref><ref id="B10-nutrients-10-00201"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ilus</surname><given-names>T.</given-names></name><name><surname>Kaukinen</surname><given-names>K.</given-names></name><name><surname>Virta</surname><given-names>L.J.</given-names></name><name><surname>Pukkala</surname><given-names>E.</given-names></name><name><surname>Collin</surname><given-names>P.</given-names></name></person-group><article-title>Incidence of malignancies in diagnosed celiac patients: A population-based estimate</article-title><source>Am. J. Gastroenterol.</source><year>2014</year><volume>109</volume><fpage>1471</fpage><lpage>1477</lpage><pub-id pub-id-type="doi">10.1038/ajg.2014.194</pub-id><pub-id pub-id-type="pmid">25047399</pub-id></element-citation></ref><ref id="B11-nutrients-10-00201"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tjellström</surname><given-names>B.</given-names></name><name><surname>Stenhammar</surname><given-names>L.</given-names></name><name><surname>Högberg</surname><given-names>L.</given-names></name><name><surname>Fälth-Magnusson</surname><given-names>K.</given-names></name><name><surname>Magnusson</surname><given-names>K.E.</given-names></name><name><surname>Midtvedt</surname><given-names>T.</given-names></name><name><surname>Sundqvist</surname><given-names>T.</given-names></name><name><surname>Norin</surname><given-names>E.</given-names></name></person-group><article-title>Gut microflora associated characteristics in children with celiac disease</article-title><source>Am. J. Gastroenterol.</source><year>2005</year><volume>100</volume><fpage>2784</fpage><lpage>2788</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2005.00313.x</pub-id><pub-id pub-id-type="pmid">16393236</pub-id></element-citation></ref><ref id="B12-nutrients-10-00201"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tjellström</surname><given-names>B.</given-names></name><name><surname>Stenhammar</surname><given-names>L.</given-names></name><name><surname>Sundqvist</surname><given-names>T.</given-names></name><name><surname>Fälth-Magnusson</surname><given-names>K.</given-names></name><name><surname>Hollén</surname><given-names>E.</given-names></name><name><surname>Magnusson</surname><given-names>K.E.</given-names></name><name><surname>Norin</surname><given-names>E.</given-names></name><name><surname>Midtvedt</surname><given-names>T.</given-names></name><name><surname>Högberg</surname><given-names>L.</given-names></name></person-group><article-title>The effects of oats on the function of gut microflora in children with coeliac disease</article-title><source>Aliment. Pharmacol. Ther.</source><year>2014</year><volume>39</volume><fpage>1156</fpage><lpage>1160</lpage><pub-id pub-id-type="doi">10.1111/apt.12707</pub-id><pub-id pub-id-type="pmid">24661128</pub-id></element-citation></ref><ref id="B13-nutrients-10-00201"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>D.J.</given-names></name><name><surname>Preston</surname><given-names>T.</given-names></name></person-group><article-title>Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism</article-title><source>Gut Microbes</source><year>2016</year><volume>7</volume><fpage>189</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1080/19490976.2015.1134082</pub-id><pub-id pub-id-type="pmid">26963409</pub-id></element-citation></ref><ref id="B14-nutrients-10-00201"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonard</surname><given-names>M.M.</given-names></name><name><surname>Sapone</surname><given-names>A.</given-names></name><name><surname>Catassi</surname><given-names>C.</given-names></name><name><surname>Fasano</surname><given-names>A.</given-names></name></person-group><article-title>Celiac disease and nonceliac gluten sensitivity: A review</article-title><source>JAMA</source><year>2017</year><volume>318</volume><fpage>647</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1001/jama.2017.9730</pub-id><pub-id pub-id-type="pmid">28810029</pub-id></element-citation></ref><ref id="B15-nutrients-10-00201"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quagliariello</surname><given-names>A.</given-names></name><name><surname>Aloisio</surname><given-names>I.</given-names></name><name><surname>Bozzicionci</surname><given-names>N.</given-names></name><name><surname>Luiselli</surname><given-names>D.</given-names></name><name><surname>D’Auria</surname><given-names>G.</given-names></name><name><surname>Martinez-Priego</surname><given-names>L.</given-names></name><name><surname>Pérez-Villarroya</surname><given-names>D.</given-names></name><name><surname>Langerholc</surname><given-names>T.</given-names></name><name><surname>Primec</surname><given-names>M.</given-names></name><name><surname>Mičetić-Turk</surname><given-names>D.</given-names></name><etal></etal></person-group><article-title>Effect of bifidobacterium breve on the intestinal microbiota of coeliac children on a gluten free diet: A pilot study</article-title><source>Nutrients</source><year>2016</year><volume>8</volume><elocation-id>660</elocation-id><pub-id pub-id-type="doi">10.3390/nu8100660</pub-id><pub-id pub-id-type="pmid">27782071</pub-id></element-citation></ref><ref id="B16-nutrients-10-00201"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>G.R.</given-names></name><name><surname>Hutkins</surname><given-names>R.</given-names></name><name><surname>Sanders</surname><given-names>M.E.</given-names></name><name><surname>Prescott</surname><given-names>S.L.</given-names></name><name><surname>Reimer</surname><given-names>R.A.</given-names></name><name><surname>Salminen</surname><given-names>S.J.</given-names></name><name><surname>Scott</surname><given-names>K.</given-names></name><name><surname>Stanton</surname><given-names>C.</given-names></name><name><surname>Swanson</surname><given-names>K.S.</given-names></name><name><surname>Cani</surname><given-names>P.D.</given-names></name><etal></etal></person-group><article-title>Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2017</year><pub-id pub-id-type="doi">10.1038/nrgastro.2017.75</pub-id><pub-id pub-id-type="pmid">28611480</pub-id></element-citation></ref><ref id="B17-nutrients-10-00201"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>G.R.</given-names></name><name><surname>Roberfroid</surname><given-names>M.B.</given-names></name></person-group><article-title>Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics</article-title><source>J. Nutr.</source><year>1995</year><volume>125</volume><fpage>1401</fpage><lpage>1412</lpage><pub-id pub-id-type="pmid">7782892</pub-id></element-citation></ref><ref id="B18-nutrients-10-00201"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>B.</given-names></name><name><surname>Whelan</surname><given-names>K.</given-names></name></person-group><article-title>Prebiotic inulin-type fructans and galacto-oligosaccharides: Definition, specificity, function, and application in gastrointestinal disorders</article-title><source>J. Gastroenterol. Hepatol.</source><year>2017</year><volume>32</volume><fpage>64</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1111/jgh.13700</pub-id><pub-id pub-id-type="pmid">28244671</pub-id></element-citation></ref><ref id="B19-nutrients-10-00201"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>C.</given-names></name><name><surname>Harris</surname><given-names>P.</given-names></name><name><surname>Ferguson</surname><given-names>L.</given-names></name></person-group><article-title>Potential benefits of dietary fibre intervention in inflammatory bowel disease</article-title><source>Int. J. Mol. Sci.</source><year>2016</year><volume>17</volume><elocation-id>919</elocation-id><pub-id pub-id-type="doi">10.3390/ijms17060919</pub-id><pub-id pub-id-type="pmid">27314323</pub-id></element-citation></ref><ref id="B20-nutrients-10-00201"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krupa-Kozak</surname><given-names>U.</given-names></name><name><surname>Drabińska</surname><given-names>N.</given-names></name><name><surname>Jarocka-Cyrta</surname><given-names>E.</given-names></name></person-group><article-title>The effect of oligofructose-enriched inulin supplementation on gut microbiota, nutritional status and gastrointestinal symptoms in paediatric coeliac disease patients on a gluten-free diet: Study protocol for a pilot randomized controlled trial</article-title><source>Nutr. J.</source><year>2017</year><volume>16</volume><pub-id pub-id-type="doi">10.1186/s12937-017-0268-z</pub-id><pub-id pub-id-type="pmid">28830428</pub-id></element-citation></ref><ref id="B21-nutrients-10-00201"><label>21.</label><element-citation publication-type="gov"><article-title>ClinicalTrials.gov</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-02-11">(accessed on 11 February 2018)</date-in-citation></element-citation></ref><ref id="B22-nutrients-10-00201"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fotschki</surname><given-names>J.</given-names></name><name><surname>Szyc</surname><given-names>A.M.</given-names></name><name><surname>Laparra</surname><given-names>J.M.</given-names></name><name><surname>Markiewicz</surname><given-names>L.H.</given-names></name><name><surname>Wróblewska</surname><given-names>B.</given-names></name></person-group><article-title>Immune-modulating properties of horse milk administered to mice sensitized to cow milk</article-title><source>J. Dairy Sci.</source><year>2016</year><volume>99</volume><fpage>9395</fpage><lpage>9404</lpage><pub-id pub-id-type="doi">10.3168/jds.2016-11499</pub-id><pub-id pub-id-type="pmid">27771084</pub-id></element-citation></ref><ref id="B23-nutrients-10-00201"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuller</surname><given-names>Z.</given-names></name><name><surname>Louis</surname><given-names>P.</given-names></name><name><surname>Mihajlovski</surname><given-names>A.</given-names></name><name><surname>Rungapamestry</surname><given-names>V.</given-names></name><name><surname>Ratcliffe</surname><given-names>B.</given-names></name><name><surname>Duncan</surname><given-names>A.J.</given-names></name></person-group><article-title>Influence of cabbage processing methods and prebiotic manipulation of colonic microflora on glucosinolate breakdown in man</article-title><source>Br. J. Nutr.</source><year>2007</year><volume>98</volume><fpage>364</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1017/S0007114507709091</pub-id><pub-id pub-id-type="pmid">17403273</pub-id></element-citation></ref><ref id="B24-nutrients-10-00201"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinttilä</surname><given-names>T.</given-names></name><name><surname>Kassinen</surname><given-names>A.</given-names></name><name><surname>Malinen</surname><given-names>E.</given-names></name><name><surname>Krogius</surname><given-names>L.</given-names></name><name><surname>Palva</surname><given-names>A.</given-names></name></person-group><article-title>Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR</article-title><source>J. Appl. Microbiol.</source><year>2004</year><volume>97</volume><fpage>1166</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2672.2004.02409.x</pub-id><pub-id pub-id-type="pmid">15546407</pub-id></element-citation></ref><ref id="B25-nutrients-10-00201"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Wei</surname><given-names>G.</given-names></name><name><surname>Pang</surname><given-names>X.</given-names></name><name><surname>Wei</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Jia</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name></person-group><article-title>Molecular profiling of the Clostridium leptum subgroup in human fecal microflora by PCR-denaturing gradient gel electrophoresis and clone library analysis</article-title><source>Appl. Environ. Microbiol.</source><year>2006</year><volume>72</volume><fpage>5232</fpage><lpage>5238</lpage><pub-id pub-id-type="doi">10.1128/AEM.00151-06</pub-id><pub-id pub-id-type="pmid">16885270</pub-id></element-citation></ref><ref id="B26-nutrients-10-00201"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuki</surname><given-names>T.</given-names></name><name><surname>Watanabe</surname><given-names>K.</given-names></name><name><surname>Fujimoto</surname><given-names>J.</given-names></name><name><surname>Miyamoto</surname><given-names>Y.</given-names></name><name><surname>Takada</surname><given-names>T.</given-names></name><name><surname>Matsumoto</surname><given-names>K.</given-names></name><name><surname>Oyaizu</surname><given-names>H.</given-names></name><name><surname>Tanaka</surname><given-names>R.</given-names></name></person-group><article-title>Development of 16S rRNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces</article-title><source>Appl. Environ. Microbiol.</source><year>2002</year><volume>68</volume><fpage>5445</fpage><lpage>5451</lpage><pub-id pub-id-type="doi">10.1128/AEM.68.11.5445-5451.2002</pub-id><pub-id pub-id-type="pmid">12406736</pub-id></element-citation></ref><ref id="B27-nutrients-10-00201"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heilig</surname><given-names>H.G.H.J.</given-names></name><name><surname>Zoetendal</surname><given-names>E.G.</given-names></name><name><surname>Vaughan</surname><given-names>E.E.</given-names></name><name><surname>Marteau</surname><given-names>P.</given-names></name><name><surname>Akkermans</surname><given-names>A.D.L.</given-names></name><name><surname>de Vos</surname><given-names>W.M.</given-names></name></person-group><article-title>Molecular diversity of Lactobacillus spp. and other lactic acid bacteria in the human intestine as determined by specific amplification of 16S ribosomal DNA</article-title><source>Appl. Environ. Microbiol.</source><year>2002</year><volume>68</volume><fpage>114</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1128/AEM.68.1.114-123.2002</pub-id><pub-id pub-id-type="pmid">11772617</pub-id></element-citation></ref><ref id="B28-nutrients-10-00201"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García-Villalba</surname><given-names>R.</given-names></name><name><surname>Giménez-Bastida</surname><given-names>J.A.</given-names></name><name><surname>García-Conesa</surname><given-names>M.T.</given-names></name><name><surname>Tomás-Barberán</surname><given-names>F.A.</given-names></name><name><surname>Carlos Espín</surname><given-names>J.</given-names></name><name><surname>Larrosa</surname><given-names>M.</given-names></name></person-group><article-title>Alternative method for gas chromatography-mass spectrometry analysis of short-chain fatty acids in faecal samples</article-title><source>J. Sep. Sci.</source><year>2012</year><volume>35</volume><fpage>1906</fpage><lpage>1913</lpage><pub-id pub-id-type="doi">10.1002/jssc.201101121</pub-id><pub-id pub-id-type="pmid">22865755</pub-id></element-citation></ref><ref id="B29-nutrients-10-00201"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCalley</surname><given-names>D.V.</given-names></name></person-group><article-title>Analysis of volatile fatty acids by capillary gas chromatography using on-column injection of aqueous solutions</article-title><source>J. High Resolut. Chromatogr.</source><year>1989</year><volume>12</volume><fpage>465</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1002/jhrc.1240120710</pub-id></element-citation></ref><ref id="B30-nutrients-10-00201"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drabińska</surname><given-names>N.</given-names></name><name><surname>Zieliński</surname><given-names>H.</given-names></name><name><surname>Krupa-Kozak</surname><given-names>U.</given-names></name></person-group><article-title>Technological benefits of inulin-type fructans application in gluten-free products—A review</article-title><source>Trends Food Sci. Technol.</source><year>2016</year><volume>56</volume><pub-id pub-id-type="doi">10.1016/j.tifs.2016.08.015</pub-id></element-citation></ref><ref id="B31-nutrients-10-00201"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salazar</surname><given-names>N.</given-names></name><name><surname>Dewulf</surname><given-names>E.M.</given-names></name><name><surname>Neyrinck</surname><given-names>A.M.</given-names></name><name><surname>Bindels</surname><given-names>L.B.</given-names></name><name><surname>Cani</surname><given-names>P.D.</given-names></name><name><surname>Mahillon</surname><given-names>J.</given-names></name><name><surname>de Vos</surname><given-names>W.M.</given-names></name><name><surname>Thissen</surname><given-names>J.P.</given-names></name><name><surname>Gueimonde</surname><given-names>M.</given-names></name><name><surname>de los Reyes-Gavilán</surname><given-names>C.G.</given-names></name><etal></etal></person-group><article-title>Inulin-type fructans modulate intestinal Bifidobacterium species populations and decrease fecal short-chain fatty acids in obese women</article-title><source>Clin. Nutr.</source><year>2015</year><volume>34</volume><fpage>501</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2014.06.001</pub-id><pub-id pub-id-type="pmid">24969566</pub-id></element-citation></ref><ref id="B32-nutrients-10-00201"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langlands</surname><given-names>S.J.</given-names></name></person-group><article-title>Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel</article-title><source>Gut</source><year>2004</year><volume>53</volume><fpage>1610</fpage><lpage>1616</lpage><pub-id pub-id-type="doi">10.1136/gut.2003.037580</pub-id><pub-id pub-id-type="pmid">15479681</pub-id></element-citation></ref><ref id="B33-nutrients-10-00201"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouhnik</surname><given-names>Y.</given-names></name><name><surname>Raskine</surname><given-names>L.</given-names></name><name><surname>Champion</surname><given-names>K.</given-names></name><name><surname>Andrieux</surname><given-names>C.</given-names></name><name><surname>Penven</surname><given-names>S.</given-names></name><name><surname>Jacobs</surname><given-names>H.</given-names></name><name><surname>Simoneau</surname><given-names>G.</given-names></name></person-group><article-title>Prolonged administration of low-dose inulin stimulates the growth of bifidobacteria in humans</article-title><source>Nutr. Res.</source><year>2007</year><volume>27</volume><fpage>187</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.nutres.2007.01.013</pub-id></element-citation></ref><ref id="B34-nutrients-10-00201"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aloisio</surname><given-names>I.</given-names></name><name><surname>Santini</surname><given-names>C.</given-names></name><name><surname>Biavati</surname><given-names>B.</given-names></name><name><surname>Dinelli</surname><given-names>G.</given-names></name><name><surname>Cencič</surname><given-names>A.</given-names></name><name><surname>Chingwaru</surname><given-names>W.</given-names></name><name><surname>Mogna</surname><given-names>L.</given-names></name><name><surname>Di Gioia</surname><given-names>D.</given-names></name></person-group><article-title>Characterization of <italic>Bifidobacterium</italic> spp. strains for the treatment of enteric disorders in newborns</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2012</year><volume>96</volume><fpage>1561</fpage><lpage>1576</lpage><pub-id pub-id-type="doi">10.1007/s00253-012-4138-5</pub-id><pub-id pub-id-type="pmid">22588500</pub-id></element-citation></ref><ref id="B35-nutrients-10-00201"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klemenak</surname><given-names>M.</given-names></name><name><surname>Dolinšek</surname><given-names>J.</given-names></name><name><surname>Langerholc</surname><given-names>T.</given-names></name><name><surname>di Gioia</surname><given-names>D.</given-names></name><name><surname>Mičetić-Turk</surname><given-names>D.</given-names></name></person-group><article-title>Administration of <italic>Bifidobacterium</italic> breve decreases the production of TNF-α in children with celiac disease</article-title><source>Dig. Dis. Sci.</source><year>2015</year><volume>60</volume><fpage>3386</fpage><lpage>3392</lpage><pub-id pub-id-type="doi">10.1007/s10620-015-3769-7</pub-id><pub-id pub-id-type="pmid">26134988</pub-id></element-citation></ref><ref id="B36-nutrients-10-00201"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medina</surname><given-names>M.</given-names></name><name><surname>de Palma</surname><given-names>G.</given-names></name><name><surname>Ribes-Koninckx</surname><given-names>C.</given-names></name><name><surname>Calabuig</surname><given-names>M.</given-names></name><name><surname>Sanz</surname><given-names>Y.</given-names></name></person-group><article-title>Bifidobacterium strains suppress in vitro the pro-inflammatory milieu triggered by the large intestinal microbiota of coeliac patients</article-title><source>J. Inflamm.</source><year>2008</year><volume>5</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.1186/1476-9255-5-19</pub-id><pub-id pub-id-type="pmid">18980693</pub-id></element-citation></ref><ref id="B37-nutrients-10-00201"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>D.A.</given-names></name><name><surname>McNulty</surname><given-names>N.P.</given-names></name><name><surname>Guruge</surname><given-names>J.L.</given-names></name><name><surname>Gordon</surname><given-names>J.I.</given-names></name></person-group><article-title>IgA response to symbiotic bacteria as a mediator of gut homeostasis</article-title><source>Cell Host Microbe</source><year>2007</year><volume>2</volume><fpage>328</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2007.09.013</pub-id><pub-id pub-id-type="pmid">18005754</pub-id></element-citation></ref><ref id="B38-nutrients-10-00201"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuohy</surname><given-names>K.M.</given-names></name><name><surname>Finlay</surname><given-names>R.K.</given-names></name><name><surname>Wynne</surname><given-names>A.G.</given-names></name><name><surname>Gibson</surname><given-names>G.R.</given-names></name></person-group><article-title>A Human volunteer study on the prebiotic effects of HP-inulin—Faecal bacteria enumerated using fluorescent in situ hybridisation (FISH)</article-title><source>Anaerobe</source><year>2001</year><volume>7</volume><fpage>113</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1006/anae.2001.0368</pub-id></element-citation></ref><ref id="B39-nutrients-10-00201"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sghir</surname><given-names>A.</given-names></name><name><surname>Gramet</surname><given-names>G.</given-names></name><name><surname>Suau</surname><given-names>A.</given-names></name><name><surname>Rochet</surname><given-names>V.</given-names></name><name><surname>Pochart</surname><given-names>P.</given-names></name><name><surname>Dore</surname><given-names>J.</given-names></name></person-group><article-title>Quantification of bacterial groups within human fecal flora by oligonucleotide probe hybridization</article-title><source>Appl. Environ. Microbiol.</source><year>2000</year><volume>66</volume><fpage>2263</fpage><lpage>2266</lpage><pub-id pub-id-type="doi">10.1128/AEM.66.5.2263-2266.2000</pub-id><pub-id pub-id-type="pmid">10788414</pub-id></element-citation></ref><ref id="B40-nutrients-10-00201"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>M.D.</given-names></name><name><surname>Lawson</surname><given-names>P.A.</given-names></name><name><surname>Willems</surname><given-names>A.</given-names></name><name><surname>Cordoba</surname><given-names>J.J.</given-names></name><name><surname>Fernandez-Garayzabal</surname><given-names>J.</given-names></name><name><surname>Garcia</surname><given-names>P.</given-names></name><name><surname>Cai</surname><given-names>J.</given-names></name><name><surname>Hippe</surname><given-names>H.</given-names></name><name><surname>Farrow</surname><given-names>J.A.</given-names></name></person-group><article-title>The phylogeny of the genus <italic>Clostridium</italic>: Proposal of five new genera and eleven new species combinations</article-title><source>Int. J. Syst. Bacteriol.</source><year>1994</year><volume>44</volume><fpage>812</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1099/00207713-44-4-812</pub-id><pub-id pub-id-type="pmid">7981107</pub-id></element-citation></ref><ref id="B41-nutrients-10-00201"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>P.</given-names></name><name><surname>Flint</surname><given-names>H.J.</given-names></name></person-group><article-title>Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine</article-title><source>FEMS Microbiol. Lett.</source><year>2009</year><volume>294</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.2009.01514.x</pub-id><pub-id pub-id-type="pmid">19222573</pub-id></element-citation></ref><ref id="B42-nutrients-10-00201"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabeerdoss</surname><given-names>J.</given-names></name><name><surname>Sankaran</surname><given-names>V.</given-names></name><name><surname>Pugazhendhi</surname><given-names>S.</given-names></name><name><surname>Ramakrishna</surname><given-names>B.S.</given-names></name></person-group><article-title>Clostridium leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease: A case-control study in India</article-title><source>BMC Gastroenterol.</source><year>2013</year><volume>13</volume><elocation-id>20</elocation-id><pub-id pub-id-type="doi">10.1186/1471-230X-13-20</pub-id><pub-id pub-id-type="pmid">23351032</pub-id></element-citation></ref><ref id="B43-nutrients-10-00201"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adebola</surname><given-names>O.O.</given-names></name><name><surname>Corcoran</surname><given-names>O.</given-names></name><name><surname>Morgan</surname><given-names>W.A.</given-names></name></person-group><article-title>Synbiotics: The impact of potential prebiotics inulin, lactulose and lactobionic acid on the survival and growth of lactobacilli probiotics</article-title><source>J. Funct. Foods</source><year>2014</year><volume>10</volume><fpage>75</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.jff.2014.05.010</pub-id></element-citation></ref><ref id="B44-nutrients-10-00201"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krupa-Kozak</surname><given-names>U.</given-names></name><name><surname>Markiewicz</surname><given-names>L.H.</given-names></name><name><surname>Lamparski</surname><given-names>G.</given-names></name><name><surname>Juśkiewicz</surname><given-names>J.</given-names></name></person-group><article-title>Administration of inulin-supplemented gluten-free diet modified calcium absorption and caecal microbiota in rats in a calcium-dependent manner</article-title><source>Nutrients</source><year>2017</year><volume>9</volume><pub-id pub-id-type="doi">10.3390/nu9070702</pub-id><pub-id pub-id-type="pmid">28684691</pub-id></element-citation></ref><ref id="B45-nutrients-10-00201"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaumont</surname><given-names>M.</given-names></name><name><surname>Portune</surname><given-names>K.J.</given-names></name><name><surname>Steuer</surname><given-names>N.</given-names></name><name><surname>Lan</surname><given-names>A.</given-names></name><name><surname>Cerrudo</surname><given-names>V.</given-names></name><name><surname>Audebert</surname><given-names>M.</given-names></name><name><surname>Dumont</surname><given-names>F.</given-names></name><name><surname>Mancano</surname><given-names>G.</given-names></name><name><surname>Khodorova</surname><given-names>N.</given-names></name><name><surname>Andriamihaja</surname><given-names>M.</given-names></name><etal></etal></person-group><article-title>Quantity and source of dietary protein influence metabolite production by gut microbiota and rectal mucosa gene expression: A randomized, parallel, double-blind trial in overweight humans</article-title><source>Am. J. Clin. Nutr.</source><year>2017</year><volume>106</volume><fpage>1005</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.3945/ajcn.117.158816</pub-id><pub-id pub-id-type="pmid">28903954</pub-id></element-citation></ref><ref id="B46-nutrients-10-00201"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>G.D.</given-names></name><name><surname>Compher</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>E.Z.</given-names></name><name><surname>Smith</surname><given-names>S.A.</given-names></name><name><surname>Shah</surname><given-names>R.D.</given-names></name><name><surname>Bittinger</surname><given-names>K.</given-names></name><name><surname>Chehoud</surname><given-names>C.</given-names></name><name><surname>Albenberg</surname><given-names>L.G.</given-names></name><name><surname>Nessel</surname><given-names>L.</given-names></name><name><surname>Gilroy</surname><given-names>E.</given-names></name><etal></etal></person-group><article-title>Comparative metabolomics in vegans and omnivores reveal constraints on diet-dependent gut microbiota metabolite production</article-title><source>Gut</source><year>2016</year><volume>65</volume><fpage>63</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2014-308209</pub-id><pub-id pub-id-type="pmid">25431456</pub-id></element-citation></ref><ref id="B47-nutrients-10-00201"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>S.</given-names></name><name><surname>Toh</surname><given-names>H.</given-names></name><name><surname>Hase</surname><given-names>K.</given-names></name><name><surname>Oshima</surname><given-names>K.</given-names></name><name><surname>Nakanishi</surname><given-names>Y.</given-names></name><name><surname>Yoshimura</surname><given-names>K.</given-names></name><name><surname>Tobe</surname><given-names>T.</given-names></name><name><surname>Clarke</surname><given-names>J.M.</given-names></name><name><surname>Topping</surname><given-names>D.L.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><etal></etal></person-group><article-title><italic>Bifidobacteria</italic> can protect from enteropathogenic infection through production of acetate</article-title><source>Nature</source><year>2011</year><volume>469</volume><fpage>543</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1038/nature09646</pub-id><pub-id pub-id-type="pmid">21270894</pub-id></element-citation></ref><ref id="B48-nutrients-10-00201"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tjellström</surname><given-names>B.</given-names></name><name><surname>Högberg</surname><given-names>L.</given-names></name><name><surname>Stenhammar</surname><given-names>L.</given-names></name><name><surname>Fälth-Magnusson</surname><given-names>K.</given-names></name><name><surname>Magnusson</surname><given-names>K.</given-names></name><name><surname>Norin</surname><given-names>E.</given-names></name><name><surname>Sundqvist</surname><given-names>T.</given-names></name><name><surname>Midtvedt</surname><given-names>T.</given-names></name></person-group><article-title>Faecal short-chain fatty acid pattern in childhood coeliac disease is normalised after more than one year’s gluten-free diet</article-title><source>Microb. Ecol. Health Dis.</source><year>2013</year><volume>24</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.3402/mehd.v24i0.20905</pub-id><pub-id pub-id-type="pmid">24082880</pub-id></element-citation></ref><ref id="B49-nutrients-10-00201"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>J.L.</given-names></name><name><surname>Yap</surname><given-names>Y.A.</given-names></name><name><surname>McLeod</surname><given-names>K.H.</given-names></name><name><surname>Mackay</surname><given-names>C.R.</given-names></name><name><surname>Mariño</surname><given-names>E.</given-names></name></person-group><article-title>Dietary metabolites and the gut microbiota: An alternative approach to control inflammatory and autoimmune diseases</article-title><source>Clin. Transl. Immunol.</source><year>2016</year><volume>5</volume><fpage>e82</fpage><pub-id pub-id-type="doi">10.1038/cti.2016.29</pub-id><pub-id pub-id-type="pmid">27350881</pub-id></element-citation></ref><ref id="B50-nutrients-10-00201"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>U.</given-names></name><name><surname>Nyman</surname><given-names>M.</given-names></name></person-group><article-title>Short-chain fatty acid formation in the hindgut of rats fed oligosaccharides varying in monomeric composition, degree of polymerisation and solubility</article-title><source>Br. J. Nutr.</source><year>2005</year><volume>94</volume><fpage>705</fpage><pub-id pub-id-type="doi">10.1079/BJN20051531</pub-id><pub-id pub-id-type="pmid">16277772</pub-id></element-citation></ref><ref id="B51-nutrients-10-00201"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanauchi</surname><given-names>O.</given-names></name><name><surname>Andoh</surname><given-names>A.</given-names></name><name><surname>Iwanaga</surname><given-names>T.</given-names></name><name><surname>Fujiyama</surname><given-names>Y.</given-names></name><name><surname>Mitsuyama</surname><given-names>K.</given-names></name><name><surname>Toyonaga</surname><given-names>A.</given-names></name><name><surname>Bamba</surname><given-names>T.</given-names></name></person-group><article-title>Germinated barley foodstuffs attenuate colonic mucosal damage and mucosal nuclear factor kappa B activity in a spontaneous colitis model</article-title><source>J. Gastroenterol. Hepatol.</source><year>1999</year><volume>14</volume><fpage>1173</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1046/j.1440-1746.1999.02025.x</pub-id><pub-id pub-id-type="pmid">10634153</pub-id></element-citation></ref><ref id="B52-nutrients-10-00201"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abela</surname><given-names>A.-G.</given-names></name><name><surname>Fava</surname><given-names>S.</given-names></name></person-group><article-title>Does the level of bacterial exposure in early life impact the risk of Type 1 diabetes?</article-title><source>Expert Rev. Clin. Immunol.</source><year>2013</year><volume>9</volume><fpage>695</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1586/1744666X.2013.814410</pub-id><pub-id pub-id-type="pmid">23971746</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="nutrients-10-00201-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Quantitative characteristics of faecal microbiota before (T0) and after (T1) the intervention, expressed by means ± SEM (standard error of the mean) and by log cells/g of faeces. * <italic>p</italic> &lt; 0.05. TBN: total bacterial counts; BIF: <italic>Bifidobacterium</italic> sp.; Clept: <italic>C. leptum</italic>; BPP: <italic>Bacteroides-Prevotella-Porphyromonas</italic>; Ccocc: <italic>Clostridium coccoides</italic>; LAC: <italic>Lactobacillus</italic> sp.</p></caption><graphic xlink:href="nutrients-10-00201-g001"></graphic></fig><table-wrap id="nutrients-10-00201-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-10-00201-t001_Table 1</object-id><label>Table 1</label><caption><p>The primers used in the real-time polymerase chain reaction (RT-PCR) analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primer</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sequence (5′ → 3′)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">T<sub>a</sub> (°C)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Total bacteria</td><td align="center" valign="middle" rowspan="1" colspan="1">UniF</td><td align="center" valign="middle" rowspan="1" colspan="1">GTGSTGCAYGGYYGTCGTCA</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">60</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B23-nutrients-10-00201" ref-type="bibr">23</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UniR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACGTCRTCCMCNCCTTCCTC</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Bifidobacterium</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">BIF-F</td><td align="center" valign="middle" rowspan="1" colspan="1">TCG CGTC(C/T)GGTGTGAAAG</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">58</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B24-nutrients-10-00201" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BIF-R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCACATCCAGC(A/G)TCCAC</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Clostridium leptum</italic> group</td><td align="center" valign="middle" rowspan="1" colspan="1">sg-Clept-F</td><td align="center" valign="middle" rowspan="1" colspan="1">GCACAAGCAGTGGAGT</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">53</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B25-nutrients-10-00201" ref-type="bibr">25</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sg-Clept-R3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CTTCCTCCGTTTTGTCAA</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Bacteroides-Prevotella-Porphyromonas</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">BPP-F</td><td align="center" valign="middle" rowspan="1" colspan="1">GGTGTCGGCTTAAGTGCCAT</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">56</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B24-nutrients-10-00201" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BPP-R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CGGA(C/T)GTAAGGGCCGTGC</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Clostridium coccoides</italic> group</td><td align="center" valign="middle" rowspan="1" colspan="1">g-ccoc-F</td><td align="center" valign="middle" rowspan="1" colspan="1">AAATGACGGTACCTGACTAA</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">58</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B26-nutrients-10-00201" ref-type="bibr">26</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">g-ccoc-R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CTTTGAGTTTCATTCTTGCGAA</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Lactobacillus</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">Lac1F</td><td align="center" valign="middle" rowspan="1" colspan="1">AGCAGTAGGGAATCTTCCA</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">58</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B27-nutrients-10-00201" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lab667</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CACCGCTACACATGGAG</td></tr></tbody></table></table-wrap><table-wrap id="nutrients-10-00201-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-10-00201-t002_Table 2</object-id><label>Table 2</label><caption><p>Last-week survey observation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Observation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Synergy 1</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Placebo</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abdominal pain <sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Everyday defecation <sup>2</sup> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"> Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">90</td><td align="center" valign="middle" rowspan="1" colspan="1">81</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Defecation No/day</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3 ± 0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.1 ± 0.2</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Normal stool consistency <sup>3</sup> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Discomfort after the intake of supplement</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Number of episodes; <sup>2</sup> during 7-day evaluation period; <sup>3</sup> no diarrhea or constipation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="nutrients-10-00201-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-10-00201-t003_Table 3</object-id><label>Table 3</label><caption><p>Short chain fatty acids (SCFAs) concentration in faecal samples before (T0) and after (T1) the intervention, expressed by means ± SEM and by μmol/g of faeces.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">SCFA</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Placebo Group</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Synergy 1 Group</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Placebo: T0 vs. T1 <sup>2</sup></th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Synergy 1: T0 vs. T1</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">T1: Placebo vs. Synergy 1 <sup>3</sup></th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T0</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T1</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T0</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T1</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Acetic</td><td align="center" valign="middle" rowspan="1" colspan="1">29.84 ± 1.93</td><td align="center" valign="middle" rowspan="1" colspan="1">28.82 ± 4.26</td><td align="center" valign="middle" rowspan="1" colspan="1">30.00 ± 3.35</td><td align="center" valign="middle" rowspan="1" colspan="1">44.06 <sup>1</sup> ± 4.13</td><td align="center" valign="middle" rowspan="1" colspan="1">0.520</td><td align="center" valign="middle" rowspan="1" colspan="1">0.047 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.020 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Propionic</td><td align="center" valign="middle" rowspan="1" colspan="1">9.91 ± 1.23</td><td align="center" valign="middle" rowspan="1" colspan="1">7.97 ± 1.55</td><td align="center" valign="middle" rowspan="1" colspan="1">10.16 ± 1.25</td><td align="center" valign="middle" rowspan="1" colspan="1">11.14 ± 0.61</td><td align="center" valign="middle" rowspan="1" colspan="1">0.692</td><td align="center" valign="middle" rowspan="1" colspan="1">0.328</td><td align="center" valign="middle" rowspan="1" colspan="1">0.048 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>Iso</italic>-butyric</td><td align="center" valign="middle" rowspan="1" colspan="1">1.41 ± 0.15</td><td align="center" valign="middle" rowspan="1" colspan="1">1.56 ± 0.33</td><td align="center" valign="middle" rowspan="1" colspan="1">1.60 ± 0.14</td><td align="center" valign="middle" rowspan="1" colspan="1">1.33 ± 0.13</td><td align="center" valign="middle" rowspan="1" colspan="1">0.678</td><td align="center" valign="middle" rowspan="1" colspan="1">0.059</td><td align="center" valign="middle" rowspan="1" colspan="1">1.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Butyric</td><td align="center" valign="middle" rowspan="1" colspan="1">8.92 ± 1.37</td><td align="center" valign="middle" rowspan="1" colspan="1">8.21 ± 1.89</td><td align="center" valign="middle" rowspan="1" colspan="1">8.02 ± 1.27</td><td align="center" valign="middle" rowspan="1" colspan="1">10.41 ± 0.89</td><td align="center" valign="middle" rowspan="1" colspan="1">0.889</td><td align="center" valign="middle" rowspan="1" colspan="1">0.047 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.292</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>Iso</italic>-valeric</td><td align="center" valign="middle" rowspan="1" colspan="1">1.43 ± 0.18</td><td align="center" valign="middle" rowspan="1" colspan="1">1.46 ± 0.23</td><td align="center" valign="middle" rowspan="1" colspan="1">1.72 ± 0.19</td><td align="center" valign="middle" rowspan="1" colspan="1">1.56 ± 0.16</td><td align="center" valign="middle" rowspan="1" colspan="1">0.515</td><td align="center" valign="middle" rowspan="1" colspan="1">0.400</td><td align="center" valign="middle" rowspan="1" colspan="1">0.419</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Valeric</td><td align="center" valign="middle" rowspan="1" colspan="1">1.55 ± 0.21</td><td align="center" valign="middle" rowspan="1" colspan="1">0.97 ± 0.16</td><td align="center" valign="middle" rowspan="1" colspan="1">1.72 ± 0.18</td><td align="center" valign="middle" rowspan="1" colspan="1">1.47 ± 0.18</td><td align="center" valign="middle" rowspan="1" colspan="1">0.030 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.123</td><td align="center" valign="middle" rowspan="1" colspan="1">0.062</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Total SCFAs</td><td align="center" valign="middle" rowspan="1" colspan="1">53.06 ± 5.52</td><td align="center" valign="middle" rowspan="1" colspan="1">48.99 ± 5.22</td><td align="center" valign="middle" rowspan="1" colspan="1">53.23 ± 6.94</td><td align="center" valign="middle" rowspan="1" colspan="1">69.95 ± 5.92</td><td align="center" valign="middle" rowspan="1" colspan="1">0.418</td><td align="center" valign="middle" rowspan="1" colspan="1">0.041 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.005 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Total BCFAs</td><td align="center" valign="middle" rowspan="1" colspan="1">2.84 ± 0.30</td><td align="center" valign="middle" rowspan="1" colspan="1">3.02 ± 0.40</td><td align="center" valign="middle" rowspan="1" colspan="1">3.32 ± 0.33</td><td align="center" valign="middle" rowspan="1" colspan="1">2.89 ± 0.28</td><td align="center" valign="middle" rowspan="1" colspan="1">0.765</td><td align="center" valign="middle" rowspan="1" colspan="1">0.132</td><td align="center" valign="middle" rowspan="1" colspan="1">0.679</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Relative BCFAs <sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>* <italic>p</italic> &lt; 0.05. <sup>1</sup> Relative concentration of the total branched-chain fatty acids (BCFAs) (sum of <italic>iso</italic>-butyic and <italic>iso</italic>-valeric acids) expressed as a percentage of the total SCFA. <sup>2</sup> Comparison between groups using Student’s <italic>t</italic>-test or the Mann–Whitney <italic>U</italic> test, as appropriate. <sup>3</sup> Comparison within groups before and after intervention using the Student’s <italic>t</italic>-test or the Wilcoxon test, as appropriate.</p></fn></table-wrap-foot></table-wrap></floats-group></article>